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ABSTRACT
Objectives: Studies have reported that the tunnelled
dialysis catheter (TDC) is associated with inferior
haemodialysis (HD) patient survival, in comparison
with arteriovenous fistula (AVF). Since many cofactors
may also affect survival of HD patients, it is unclear
whether the greater risk for survival arises from TDC
per se, or from associated conditions. Therefore, the
aim of this study was to determine, in a multivariate
analysis, the long-term outcome of HD patients, with
respect to vascular access (VA).
Design: Retrospective cohort study.
Participants: This retrospective cohort study included
all 156 patients with a TDC admitted at University
Hospital Merkur, from 2010 to 2012. The control
group consisted of 97 patients dialysed via AVF. The
groups were matched according to dialysis unit and
time of VA placement. The site of choice for the
placement of the TDC was the right jugular vein.
Kaplan-Meier analysis with log-rank test was used to
assess patient survival. Multivariate Cox regression
analysis was used to determine independent variables
associated with patient survival.
Primary outcome measures: Patient survival with
respect to VA.
Results: The cumulative 1-year survival of patients
who were dialysed exclusively via TDC was 86.4% and
of those who were dialysed exclusively via AVF, survival
was 97.1% (p=0.002). In multivariate Cox regression
analysis, male sex and older age were independently
negatively associated with the survival of HD patients,
while shorter HD vintage before the creation of the
observed VA, hypertensive renal disease and
glomerulonephritis were positively associated with
survival. TDC was an independent risk factor for
survival of HD patients (HR 23.0, 95% CI 6.2 to 85.3).
Conclusion: TDC may be an independent negative
risk factor for HD patient survival.
INTRODUCTION
The number of patients with end-stage renal
disease (ESRD) in need of renal replacement
therapy increases progressively in Europe
and worldwide.1 This puts chronic kidney
disease (CKD) among the signiﬁcant factors
of morbidity and mortality, and represents a
growing public health issue.
In patients on haemodialysis (HD) treat-
ment, possible long-term vascular access
(VA) types are: arteriovenous ﬁstula (AVF),
arteriovenous graft (AVG) and tunnelled HD
central venous catheter (TDC). Since native
AVF, described by Brescia and Cimino in
1966, has the longest survival and the lowest
frequency of complications among all other
types of VA for HD, it should be the ﬁrst
choice for VA whenever possible.1–3 However,
there are vast differences in the use of
certain VA types in different countries and
the use of TDC is still noticeably high, in
spite of current guidelines. The rate of
patients who are dialysed via TDC among all
patients on HD varies from only 1.6% in
Japan up to 52% in Canada.4 In Croatia,
∼20% of patients are dialysed via TDC, while
the rest are dialysed via AVF (M Knotek, per-
sonal communication, 2015). AVG is infre-
quently used in Croatia.
Strengths and limitations of this study
▪ This is a retrospective cohort study in which well
matched patients followed by multiple dialysis
centres were included. Therefore, study results
account for variations in routine patient care at
different centres and are reflective of real-life
practice. This is important, because a prospect-
ive randomised trial comparing patient survival
with respect to vascular access type (arterioven-
ous fistula and tunnelled dialysis catheter) is
highly unlikely.
▪ Main outcomes (patient and vascular access sur-
vival) were analysed by multivariate analysis.
▪ The main limitation of this study is its retrospect-
ive and non-randomised design. However, the
two patient groups were well matched in the
majority of variables that may have affected the
outcome.
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Central venous catheters (CVCs) are used for the
rapid establishment of adequate VA when there is an
urgent need for HD, as a bridge during AVF maturation
process and in patients who have eventually exhausted
all other VA types.1 3 5 According to the kidney disease
outcomes quality initiative (K/DOQI) guidelines, tem-
porary catheters should be used for up to 1 week, while
the use of TDC is recommended in all other cases
where catheter use is unavoidable.6 TDCs are usually
placed according to the modiﬁed Seldinger method.7
The insertion site of choice should be the right internal
jugular vein.8 Alternatively, TDCs can be inserted
through the subclavian or femoral vein. The subclavian
vein should generally be avoided because of the high
incidence of stenosis and thrombosis, while the femoral
vein should be considered only when all other insertion
sites have been excluded.1 The advantages of the TDC
include the ability to use it immediately after placement,
no repeated venipuncture and no haemodynamic conse-
quences, and no need for a vascular surgeon during
placement.4 Nevertheless, TDCs are associated with sig-
niﬁcantly higher long-term risk of death, infections, car-
diovascular events and hospitalisation in comparison
with other VA types.9 However, at the same time, some
of the associated conditions and diseases affect patient
survival, as well as VA choice and survival. Therefore,
although many studies show that TDCs are associated
with poorer patient survival, it is not entirely clear
whether the risk arises from the TDC exclusively, or
from the associated conditions and diseases that are
often present in patients who are dialysed via TDC.9 10
The aim of this study was to determine HD patient
and VA survival with respect to VA type.
PATIENTS AND METHODS
Patients
This retrospective cohort study was approved by the
Hospital Ethics Committee of the University Hospital
Merkur, Zagreb, Croatia. Patients gave their written
informed consent for anonymised HD data collection
for research purposes. We analysed the survival of
patients dialysed via a TDC in comparison with a group
of patients who were dialysed via an AVF. We also ana-
lysed TDC survival. The study included a total of 253
patients who were treated with HD in 21 dialysis centre
in Croatia; median 16 (IQR 10, 21) per centre. With
respect to VA, the TDC:AVF ratio was approximately 2:1.
The study subjects were selected to include all 156
patients who received a total of 190 TDC at the Renal
Division in University Hospital Merkur, from the begin-
ning of 2010 to the end of 2012. Then, 97 patients who
were dialysed via AVF were selected from the same dialy-
sis centres. Eligible patients dialysed via AVF had to start
with HD treatment at about the same time as patients
dialysed via TDC. The insertion site of choice for the
TDC was the right jugular vein. Other sites were used in
case of inability to use the right jugular vein or when
exchanging over a previously inserted TDC in another
vein. All TDCs were manufactured by Medcomp Inc
(Harleysville, Pennsylvania, USA). For an internal
jugular and subclavian approach, either SST28SE or
SST32SE catheters were used, while SST40SE catheters
were used for a femoral approach. All catheters were
14 Fr.
Methods
Data were collected from the Renal Division TDC place-
ment programme database and by a questionnaire sent
to the 21 HD centres where patients underwent TDC
placement procedure in our division. In the question-
naire, we asked for the following information: demo-
graphic data, the date of ﬁrst HD, history of a temporary
CVC before the observed TDC, history of an attempt to
create an AVF or history of a functional AVF that ceased
to function, the cause of CKD, concomitant diseases,
history of catheter sepsis, history of an infection of the
TDC tunnel, whether there were problems with wound
healing after TDC placement, whether there were mech-
anical problems with the TDC and what solution the
TDC problem was usually solved with on the completion
of HD treatment. If the TDC was functional, information
on the blood pump speed, and on arterial and venous
pressure during HD treatment, was inquired about. If
TDC ceased to function, we recorded the date of cessa-
tion of TDC function, the reason for cessation of TDC
function, current VA if the patient was still treated with
HD, the date of transplantation if the patient underwent
a kidney transplantation and the date of death if the
patient died. A similar, modiﬁed questionnaire was used
to collect data about patients who were dialysed via AVF.
Statistical analysis
Numerical data are presented as mean±SD in case of
continuous variables with normal distribution or as
median with IQR in case of non-normal distribution.
The difference between two groups regarding continu-
ous variables was tested with Student’s t test in normal
distributed variables or with Mann-Whitney’s χ2 test.
Survival analysis, which included patient survival, overall
VA survival and death-censored VA survival, was per-
formed using Kaplan-Meier analysis. Univariate and
multivariate Cox regression were performed to deter-
mine variables independently associated with patient
and VA survival. All variables that were associated with
respective outcome in bivariate analysis (at p≤0.1) were
included in the multivariate Cox regression. Results are
presented as HR with the corresponding 95% CI.
Statistical signiﬁcance was considered at p value <0.05.
All statistical analyses were performed using SPSS V.17.0.
RESULTS
Characteristics of patients dialysed via TDC
Patient characteristics are shown in table 1. There were
156 patients dialysed via TDC. The cause of ESRD was
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diabetic nephropathy in 42.3% of patients, hypertensive
kidney disease in 23.1%, glomerulonephritis in 9.6%,
polycystic kidney disease in 5.8% and other diseases in
19.2% of patients. Temporary dialysis catheter use prior
to the observed TDC was noted in 69.9% of patients,
20.5% had previous TDC and 50.6% had an attempt to
create an AVF or an AVF that ceased to function. During
follow-up, 152 (97.4%) patients were dialysed via TDC
exclusively, while 4 (2.6%) switched to AVF.
Characteristics of patients dialysed via AVF
There were 97 patients dialysed via AVF. The cause of
ESRD was diabetic nephropathy in 40.2% of patients,
hypertensive kidney disease in 20.6%, glomeruloneph-
ritis in 11.3%, polycystic kidney disease in 10.3% and
other diseases in 17.5% of patients. An attempt to create
an AVF or an AVF that ceased to function prior to the
observed AVF was seen in 23.7% of patients. During
follow-up, 91 (93.8%) patients were dialysed via AVF
exclusively, while 6 (6.2%) switched to a TDC. Patient
characteristics are also shown in table 1.
Patient survival
Patient survival is shown in ﬁgure 1A. Cumulative 1-year
overall patient survival since the initiation of HD treat-
ment was 93.2%. In univariate analysis of risk factors for
the overall patient survival, there were eight negative risk
factors: TDC as current VA (p=0.001), TDC as an exclu-
sive VA (p=0.001), male gender (p=0.065), older age at
the initiation of HD treatment (p=0.006), concomitant
diabetes mellitus (p=0.021), stroke in patient’s history
(p=0.028), concomitant coronary heart disease
(p=0.017) and prior peripheral artery revascularisation
(p=0.028). Factors positively associated with overall
patient survival were shorter HD vintage prior to the
observed VA (p=0.004) and an attempt to create an AVF
or history of an AVF that ceased to function prior to the
current VA (p=0.037). With respect to ESRD, hyperten-
sive renal disease (p=0.001) and glomerulonephritis
(p=0.002) were positively associated with overall patient
survival. The results of univariate analysis are shown in
table 2. In the multivariate Cox regression, two factors
turned out as independent negative risk factors for
overall patient survival: male gender (p=0.012) and
older age at the initiation of HD treatment (p=0.037).
Shorter HD vintage prior to the observed VA (p<0.001),
hypertensive renal disease (p=0.002) and glomerulo-
nephritis (p=0.018) were independently positively
associated with overall patient survival. TDC was inde-
pendently negatively associated with patient survival in
the multivariate analysis (HR 23.0, 95% CI 6.2 to 85.3).
Patient survival with respect to VA is shown in ﬁgure 1B.
Cumulative 1-year survival of patients who were dialysed
exclusively via TDC was 91.2% and of those who were dia-
lysed exclusively via AVF, 97.1% (p=0.001). With respect to
VA conversion, 1-year survival of patients who were con-
verted from AVF to TDC was 95% (p=0.102 in comparison
with AVF as an exclusive VA; p=0.002 in comparison with
TDC as an exclusive VA).
In univariate analysis of risk factors for the survival of
patients who were dialysed exclusively via TDC, there
were four negative risk factors: male gender (p=0.010),
concomitant diabetes mellitus (p=0.006), concomitant
coronary artery disease (p=0.004) and prior peripheral
artery revascularisation (p=0.003). Factors positively asso-
ciated with survival were shorter HD vintage prior to the
current VA (p<0.001), an attempt to create an AVF or an
AVF that ceased to function prior to the current VA
(p=0.001), hypertensive renal disease (p=0.001) and
glomerulonephritis (p=0.006). The results of univariate
analysis are shown in table 2. In the multivariate Cox
regression, only male gender turned out as an inde-
pendent negative risk factor (p=0.019), while shorter
HD vintage prior to the current VA (p<0.001), an
attempt to create an AVF or an AVF that ceased to func-
tion prior to the current VA (p=0.039) and hypertensive
kidney disease as the cause of ESRD were independently
positively associated with survival.
Table 1 Characteristics of patients
All patients TDC AVF p Value
Age of patients at initiation of HD treatment (years)* 62.7±14.0 62.1±14.4 63.9±13.2 0.215
Age of patients at VA creation (years)* 63.8±13.9 63.7±14.2 64.0±13.4 0.737
Age of patients at end of follow-up (years)* 65.8±13.9 65.2±14.3 66.9±12.9 0.248
Sex (male/female) 152/101 88/68 64/33 0.081
HD vintage (days)† 607 (335, 1088) 658 (374, 1114) 536 (320, 1139) 0.836
HD vintage before observed VA creation (days)† 50 (5, 348) 204 (33, 799) 7 (0, 66) <0.001
Diabetes mellitus 42.7% 44.2% 40.2% 0.464
Coronary heart disease 20.6% 20.5% 20.6% 0.851
Stroke 11.9% 16.7% 4.1% 0.001
Peripheral vascular disease 20.2% 19.9% 20.6% 0.902
Peripheral artery revascularisation 6.3% 6.4% 6.2% 0.228
Partial or total limb amputation 14.2% 15.4% 12.4% 0.599
*Mean±SD.
†Median with IQR.
AVF, arteriovenous fistula; HD, haemodialysis; TDC, tunnelled haemodialysis catheter; VA, vascular access.
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VA survival
Among the total of 190 TDCs, 124 (65.3%) were placed
de novo. Altogether, 58% of TDCs were placed in the
right jugular vein, 11.2% in the left jugular vein, 17.6%
in the right subclavian vein, 8.5% in the left subclavian
vein, 2.7% in the right femoral vein and 2.1% in the left
femoral vein. The most frequent long-term complica-
tions were TDC thrombosis and infection; 6.8% of infec-
tions led to TDC-associated sepsis and 6.3% were tunnel
infections. Of these, 35.3% of infections were cured
without catheter removal. The TDC was replaced in
47.1% of infection cases and permanently removed in
5.9% of cases. Of the infections, 11.8% ended in a lethal
outcome. The wound healing problems after TDC place-
ment occurred in 5.8% of patients. Mechanical pro-
blems (rupture or separation of catheter lines, puncture
or rupture of the clamp or cap) were reported in 7% of
cases. The mean blood pump speed for TDCs in use was
288±36 mL/min, mean pressure in the venous line of
the dialysis machine was 158±35 mm Hg while mean
pressure in the arterial line was −184±39 mm Hg. TDCs
were closed with sodium citrate (Duraloc) exclusively in
20.3% of cases, and in 67.4% cases, with heparin exclu-
sively, the rest were closed either with sodium citrate or
with heparin. During HD treatment it was necessary to
switch TDC lines every time in 10.5% of TDCs, occasion-
ally in 62.1% and never in 27.4%. During this monitor-
ing process, 50% of TDCs ceased to function. The
causes of cessation are shown in table 3.
TDC death-censored survival is shown in ﬁgure 2.
One-year death-censored TDC survival was 76.7%. In
univariate analysis, there were four risk factors nega-
tively associated with TDC survival: an attempt to create
an AVF or an AVF that ceased to function prior to the
current VA (p=0.010), TDC-associated sepsis (p<0.001),
tunnel infection (p<0.001) and mechanical problems
with TDCs (p<0.001). In the multivariate Cox regres-
sion, an attempt to create an AVF or an AVF that
ceased to function prior to the current VA (p=0.014),
mechanical problems with the TDC (p=0.002) and
TDC line puncture or rupture (p=0.001) were inde-
pendently negatively associated with TDC death-
censored survival.
The mean blood pump speed for AVF in use was 318
±36 mL/min, mean pressure in the venous line of the
dialysis machine was 137±32 mm Hg, while mean pres-
sure in the arterial line was −154±37 mm Hg. During
this monitoring process, 13.4% of AVFs ceased to func-
tion. The causes of cessation are shown in table 4.
AVF death-censored survival is shown in ﬁgure 2.
One-year death-censored AVF survival was 96%. In uni-
variate analysis, male gender was negatively associated
with AVF death-censored survival (p=0.004). No variable
was independently associated with death-censored AVF
survival in multivariate Cox regression.
VA death-censored survival (both TDC and AVF) is shown
in ﬁgure 2. In univariate analysis, there were three factors
negatively associated with VA death-censored survival: TDC
as VA type (p<0.001), an attempt to create an AVF or an
AVF that ceased to function prior to the observed VA
(p<0.001) and TDC as an exclusive VA (p<0.001). In multi-
variate Cox regression, AVF as an exclusive VA was inde-
pendently positively associated with VA survival (p<0.001).
DISCUSSION
This analysis deﬁned factors associated with VA and
patient survival in a real-life situation, in a patient popu-
lation treated in 21 dialysis centres across Croatia. The
cause of ESRD in a studied group of patients completely
Figure 1 (A) Kaplan-Meier curve for overall HD patient
survival. HD, haemodialysis (B) Kaplan-Meier curve for HD
patient survival with respect to vascular access. AVF,
arteriovenous fistula, TDC, tunnelled haemodialysis catheter;
VA, vascular access.
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coincided with Croatian Registry of Renal Replacement
Therapy data.11 The frequency of concomitant diseases
was similar to that in other developed countries.
One-year patient survival in this study was excellent,
probably reﬂecting good HD care in Croatia. Female
gender was independently positively associated with
overall patient survival. This was previously shown in the
Choices for Healthy Outcomes in Caring for ESRD
study by Astor et al,12 where TDC as current VA, male
gender and older age at initiation of HD treatment were
independently negatively associated with overall patient
survival.
In a recent cohort study of 3752 dialysis patients,
1-year survival of patients who were dialysed via TDC was
75% and factors independently negatively associated
with survival were age at ﬁrst treatment, late referral, cor-
onary artery disease, peripheral vascular disease and
cerebrovascular disease. One-year survival of patients
dialysed via AVF was 90%.13 There are several other
studies that showed a statistically signiﬁcant difference in
patient survival with respect to VA type.12 14 Our study
largely conﬁrms previously observed statistically signiﬁ-
cant difference in survival between the two groups of
HD patients and in the identiﬁed independent risk
factors for the survival of patients who were dialysed via
TDC. However, our results showed that patients included
in this study who were dialysed via TDC and those who
were dialysed via AVF had better survival in comparison
Table 2 Patient survival—the results of univariate and multivariate analysis
1-year
survival (%)
2-year
survival (%) p Value HR (95% CI) p Value
VA type
TDC 91.2 77.7 0.001* 3.8 (1.6 to 8.9) 0.002
AVF 97.2 95.7
Sex
Male 91.1 79.0 0.065* 1.7 (0.9 to 3.2) 0.069
Female 96.5 89.0
An attempt to create an AVF or an AVF that ceased to function prior to the observed VA
Yes 95.7 87.4 0.037* 1.8 (1.1 to 3.1) 0.040
No 91.3 78.6
Concomitant diabetes mellitus
Yes 91.2 76.7 0.021* 0.5 (0.3 to 0.9) 0.023
No 94.8 87.5
Stroke in patient’s history
Yes 94.6 72.9 0.028* 0.5 (0.3 to 0.9) 0.031
No 93.0 84.9
Concomitant coronary heart disease
Yes 93.2 68.9 0.017* 0.5 (0.3 to 0.9) 0.019
No 93.3 88.2
Peripheral artery revascularisation
Yes 100 57.9 0.028* 0.5 (0.2 to 0.9) 0.033
No 92.7 86.2
VA conversion
A 86.4 64.8 <0.001* 2.8 (1.5 to 5.0) 0.001
B 97.1 95.5
C 95.0 86.5
Hypertensive kidney disease 96.0 96.0 <0.001* 0.2 (0.1 to 0.5) 0.002
Glomerulonephritis 100 100 <0.001* 0 (0 to 0.3) 0.018
The age of patients at the initiation of HD
treatment (years)
1.0 (1 to 1.1) 0.037
Time from the initiation of HD treatment to the
observed VA creation (months)
0.8 (0.7 to 0.9) 0.006
A: TDC as an exclusive VA; B: AVF as an exclusive VA; C: the conversion of VA from AVF to TDC.
*Log-rank (Mantel-Cox) test.
AVF, arteriovenous fistula; HD, haemodialysis; TDC, tunnelled haemodialysis catheter; VA, vascular access.
Table 3 Causes of TDC function cessation
Cause N (%)
Death of a patient 37 (43.0)
TDC thrombosis 14 (16.3)
TDC infection 9 (10.5)
VA conversion from TDC to AVF 8 (9.3)
Kidney transplantation 6 (7.0)
Recovery of renal function 2 (2.3)
Catheter fell out 1 (1.2)
AVF, arteriovenous fistula; TDC, tunnelled haemodialysis catheter;
VA, vascular access.
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with previously published studies. Several studies showed
that patient survival is associated with VA conversion and
is better in patients who are converted from TDC to AVF
during the ﬁrst year of HD treatment.10 15 Although our
study did not include enough patients who underwent
this kind of VA conversion analysis, we showed that sur-
vival was not signiﬁcantly different in patients who were
dialysed exclusively via AVF and those who were con-
verted from AVF to TDC. Therefore, it is likely that there
are other factors besides TDC that are responsible for
lower survival of patients dialysed exclusively via TDC.
Multivariate Cox regression showed that VA type is an
independent risk factor for patient survival. The associ-
ation of VA type with patient survival is controversial.
Multiple studies, including ours, suggested negative cor-
relation between TDC and patient survival.9 10 12 14 16
On the other hand, according to several retrospective
studies, TDC per se may not be negatively associated
with poor patient survival.17 18 This issue could be clari-
ﬁed only by prospective randomised control studies,
which are difﬁcult to perform.
Studying the association of TDCs with HD patient out-
comes is important, because the number of patients who
are dialysed via TDC is steadily increasing.19 20 A ∼20%
of dialysis patients in Croatia are dialysed via TDC (M
Knotek, personal communication). Although K/DOQI
guidelines recommend that <10% of all patients treated
with HD should be dialysed via TDC, this goal remains
unachieved.20 The number of patients who initiate HD
treatment via TDC is also much higher than recom-
mended.19 Possible reasons are late referral to a neph-
rologist, a lack of surgeon availability for AVF creation
and an increasing proportion of elderly patients who are
not eligible for AVF creation due to their poor blood
vessel status.21
In one British study of 812 TDC, 1-year death-
censored TDC survival of 61% was demonstrated.22
Another study of 200 Tesio catheters reported a 1-year
death-censored catheter survival of 60%.23 Our results
show signiﬁcantly better 1-year TDC survival, in com-
parison with these previously published studies.
According to guidelines, the right jugular vein was the
insertion site of choice at our centre, but this study did
not ﬁnd a statistically signiﬁcant difference between
the insertion site and TDC survival (data not shown).
This may be due to the low power of the study for
this analysis, as number of TDC insertions at other sites
was low.
In conclusion, we found in the present study that the
TDC may be an independent negative risk factor for HD
patient survival and that it has a shorter lifetime in com-
parison with AVF. However, our results stem from a retro-
spective study, and an adequately powered prospective
randomised controlled trial would be necessary to prove
causality of the association of TDC with worse HD
patient outcome.
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Figure 2 Kaplan-Meier curve for vascular access
death-censored survival. AVF, arteriovenous fistula, TDC,
tunnelled haemodialysis catheter; VA, vascular access.
Table 4 Causes of AVF function cessation
Cause N (%)
Death of a patient 5 (38.5)
AVF thrombosis 4 (30.8)
Vein rupture 2 (15.4)
Difficult AVF puncture or inadequate blood flow 2 (15.4)
AVF, arteriovenous fistula.
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